High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

2001907 citationsJournal Articlebronze Open Access

Authors

This trial demonstrated a significant treatment benefit of HDI versus GMK in terms of RFS and OS in melanoma patients at high risk of recurrence.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 19, Issue 9, pp. 2370-2380

Field-Weighted Citation Impact: 20.61